STOCK TITAN

Adagene doses first patient in ADG138 Phase 1 trial

Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
6-K

Rhea-AI Filing Summary

Adagene Inc. (ADAG) dosed the first patient in its first-in-human Phase 1 study of ADG138, a double-masked HER2×CD3 bispecific T-cell engager. The open-label study is designed for patients with HER2-positive advanced solid tumors and will evaluate safety and preliminary efficacy and determine a recommended Phase 2 dose. Dose escalation starts at 2 mg, with subsequent doses guided by emerging clinical data.

Adagene reported that in preclinical models, ADG138 showed approximately 220-fold and greater than 1,000-fold reductions in binding to HER2 and CD3, respectively, compared with its unmasked form. The company also said it was tolerated at doses over 300-fold higher than an unmasked T-cell engager, with markedly reduced cytokine release. These are preclinical findings; the Phase 1 study is intended to evaluate ADG138 in patients.

ADG138 starting dose 2 mg Phase 1 dose escalation
Reduction in HER2 binding Approximately 220-fold Preclinical models, compared with unmasked ADG138
Reduction in CD3 binding Greater than 1,000-fold Preclinical models, compared with unmasked ADG138
Tolerated dose comparison Over 300-fold higher ADG138 compared with an unmasked T-cell engager in preclinical testing
bispecific T-cell engager medical
"a double-masked HER2×CD3 bispecific T-cell engager"
A bispecific T‑cell engager is a lab-made protein that binds both a cancer cell and a patient’s immune T cell at the same time, bringing them together so the T cell can attack and kill the cancer cell. For investors, these drugs matter because they represent a targeted immunotherapy approach with potential for strong effectiveness but also unique safety and regulatory risks—think of it as a matchmaker that can unlock powerful results if it works safely and reliably.
IgG1-based heterodimeric format technical
"built on an IgG1-based format"
SAFEbody® precision masking technology technical
"Adagene’s proprietary SAFEbody® precision masking technology"
tumor microenvironment medical
"activated within the tumor microenvironment"
The tumor microenvironment is the immediate area surrounding a cancer cell, made up of nearby cells, blood vessels, and support structures that influence how the cancer grows and spreads. It functions like a bustling neighborhood that can either help or hinder the tumor’s development. For investors, understanding changes in this environment can signal the effectiveness of treatments and potential shifts in a cancer-related market.
cytokine release medical
"with markedly reduced cytokine release"
Cytokine release is the surge of small signaling proteins produced by the immune system that coordinate inflammation and other defense actions; this reaction is like an alarm system that can help fight threats but may also trigger widespread inflammation if it becomes excessive. For investors, cytokine release matters because therapies that provoke or prevent it shape a drug’s safety profile, clinical trial results, regulatory approval chances and market acceptance, all of which can materially affect a company’s valuation.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is ADAG's ADG138 Phase 1 study designed to evaluate?

It will evaluate safety and preliminary efficacy in patients with HER2-positive advanced solid tumors and determine a recommended Phase 2 dose. The study is open-label.

What is the starting dose for ADAG's ADG138 study?

The starting dose is 2 mg; subsequent doses will be guided by emerging clinical data.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-
16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the Month of November 2026

 

Commission File Number: 001-39997

 

 

 

Adagene Inc.

 

 

 

4F, Building C14, No. 218

Xinghu Street, Suzhou Industrial Park

Suzhou, Jiangsu Province, 215123

People’s Republic of China

+86-512-8777-3632

(Address of principal executive offices)

 

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F x   Form 40-F ¨

 

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Adagene Inc.
   
  By: /s/ Peter Luo
  Name: Peter Luo
  Title: Chief Executive Officer
   
Date: November 19, 2026  

 

 

 

 

EXHIBIT INDEX

 

Exhibit   Description
     
99.1   Press release titled “Adagene Announces First Patient Dosed in Phase 1 Study of ADG138, a Novel HER2×CD3 Double-Masked Bispecific T-Cell Engager”

 

 

 

 

Exhibit 99.1

 

 

 

Adagene Announces First Patient Dosed in Phase 1 Study of ADG138, a Novel HER2×CD3 Double-Masked Bispecific T-Cell Engager

 

First-in-human study will enroll patients with HER2-positive advanced solid tumors

 

ADG138 design includes proprietary IgG1-based heterodimeric format and SAFEbody® double masking to support prolonged circulation and tumor-selective accumulation and activation

 

SAN DIEGO, Calif. November 19, 2026 – Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced that the first patient has been dosed in a first-in-human Phase 1 study of ADG138, a double-masked HER2×CD3 bispecific T-cell engager built on an IgG1-based format and Adagene’s proprietary SAFEbody® precision masking technology.

 

“Dosing the first patient with ADG138 is an important step in moving our double-masked T-cell engager from preclinical research into the clinic,” said Peter Luo, Ph.D., Chairman, CEO and President of R&D at Adagene. “Our preclinical data showed that masking both the HER2 and CD3 binding sites preserved ADG138’s antitumor activity, including in Enhertu (DS-8201)-resistant models, while reducing cytokine release and widening the therapeutic window compared with an unmasked T-cell engager.

 

“Clinical experience with muzastotug, our masked anti-CTLA-4 SAFEbody in IgG1 format, now includes more than 250 patients dosed with high, repeated dosing, and continuous treatment beyond two years in some patients. Together with ADG138’s robust preclinical findings, this reinforces our confidence in extending SAFEbody technology to T-cell engagers. We look forward to evaluating ADG138’s safety and preliminary efficacy in heavily pretreated patients who have progressed after multiple lines of therapies, including standard-of-care and investigational HER2-directed antibody-drug conjugates.”

 

The open-label Phase 1 study is designed to evaluate the safety and preliminary efficacy of ADG138 in patients with HER2-positive advanced solid tumors and determine the recommended Phase 2 dose. Dose escalation will begin with a starting dose of 2 mg of ADG138, and subsequent doses will be guided by emerging clinical data.

 

1

 

 

 

 

About ADG138

 

ADG138 is a double-masked HER2×CD3 bispecific T cell engager designed using Adagene’s proprietary IgG-based heterodimeric format and SAFEbody® precision masking technology, which covalently links masking peptides to both the HER2- and CD3-binding arms of the molecule. In its inactivated state, ADG138 is designed to minimally bind HER2-expressing cancer cells and T cells; the molecule becomes activated within the tumor microenvironment and engages T cells to selectively kill HER2-expressing tumor cells while limiting off-target toxicity.

 

In preclinical models, the double-masked ADG138 has achieved approximately 220-fold and greater than 1,000-fold reductions in binding to HER2 and CD3, respectively, compared to its unmasked form. Upon activation in the tumor microenvironment, ADG138 enables highly efficient T cell-mediated tumor cell killing, driving tumor regression in both HER2-high and HER2-low tumor models, including a model refractory and/or resistant to the Enhertu (DS-8201). ADG138 has also shown synergistic anti-tumor activity in combination with anti-CTLA-4, anti-PD-1, or anti-CD137 antibodies. In addition, ADG138 was tolerated at doses over 300-fold higher than an unmasked T-cell engager, with markedly reduced cytokine release and a favorable pharmacokinetic profile, including a longer apparent half-life and higher systemic exposure than the parental molecule.

 

About Adagene

 

Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biotechnology company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address globally unmet patient needs. The company has forged strategic collaborations with reputable global partners that leverage its SAFEbody® precision masking technology in multiple approaches at the vanguard of science.

 

Powered by its proprietary Dynamic Precision Library (DPL) platform, composed of NEObody™, SAFEbody, and POWERbody™ technologies, Adagene’s highly differentiated pipeline features novel immunotherapy programs. The company’s SAFEbody technology is designed to address safety and tolerability challenges associated with many antibody therapeutics by using precision masking technology to shield the binding domain of the biologic therapy. Through activation in the tumor microenvironment, this allows for tumor-specific targeting of antibodies, while minimizing on-target off-tumor toxicity in healthy tissues.

 

Adagene’s lead clinical program, muzastotug (ADG126), is a masked, anti-CTLA-4 SAFEbody with FDA Fast Track designation that targets a unique epitope of CTLA-4 in regulatory T cells (Tregs) in the tumor microenvironment. Muzastotug is currently in Phase 1b/2 and Phase 2 clinical studies in combination with anti-PD-1 therapy, particularly focused on microsatellite stable (MSS) metastatic colorectal cancer (CRC). Validated by ongoing clinical research, the SAFEbody platform can be applied to a wide variety of antibody-based therapeutic modalities, including Fc-empowered antibodies, antibody-drug conjugates, and bi/multi-specific T-cell engagers.

 

For more information, please visit: https://investor.adagene.com.

 

Follow Adagene on WeChat, LinkedIn and X.

 

2

 

 

 

 

SAFEbody® is a registered trademark in the United States, China, Australia, Japan, Singapore, and the European Union.

 

Safe Harbor Statement

 

This press release contains forward-looking statements, including statements regarding ADG138’s potential therapeutic benefits, the intended effects of its dual-masking design, the objectives of its Phase 1 study and starting-dose strategy, and Adagene’s anticipated preclinical activities, clinical development, regulatory milestones and commercialization of its product candidates. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including but not limited to Adagene’s ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may not support further development or regulatory approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of Adagene’s drug candidates; Adagene’s ability to achieve commercial success for its drug candidates, if approved; Adagene’s ability to obtain and maintain protection of intellectual property for its technology and drugs; Adagene’s reliance on third parties to conduct drug development, manufacturing and other services; Adagene’s limited operating history and Adagene’s ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates; Adagene’s ability to enter into additional collaboration agreements beyond its existing strategic partnerships or collaborations, as well as those risks more fully discussed in the “Risk Factors” section in Adagene’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Adagene, and Adagene undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

 

Investor Contacts

 

Raymond Tam
Raymond_tam@adagene.com

 

Corey Davis
LifeSci Advisors
cdavis@lifesciadvisors.com

 

Media Contact

 

Michael Fitzhugh
LifeSci Communications
mfitzhugh@lifescicomms.com

 

3

 

Filing Exhibits & Attachments

1 document

Keep reading